Watch the video recording on YouTube: https://youtu.be/BM6x59oMnKg?si=qF0xDvgUMvU60ctP

2025 has been the start of a bull period for psychedelic medicine.

​Psychedelic Biotechs like GH Research, Compass Pathways and Lykos Therapeutics are releasing impressive, late stage clinical trial data

​Capital is following the data: Cybin just raised $500M and Johnson and Johnson's Ketamine-inspired antidepressant Spravato broke $1B+ / year of topline.

​A new administration seems surprisingly interested in accelerating the FDA approval of psychedelics as treatments for mental health disorders

​Learn how top VCs and LPs are mapping and allocating to this exciting space in this special event designed for family offices and HNWIs.

​You will learn:

​The contrasting approaches that biotech and pharma are taking to commercialize psychedelic medicine

​Where we see the highest-leverage points for investing

​Lessons from past failures

​And of course there will be plenty of time for interaction and Q&A

​This event is run by Brom Rector and Sam Tabone of XEIA, a venture capital fund that invests in "Human 3 - the next epoch of human health, wellbeing and performance". As part of their Human 3 thesis, they have invested in 8 psychedelic medicine companies from pre-seed to pre-IPO.